Beijing Luzhu Biotechnology Co., Ltd. (LUZHU BIOTECH-B) filed its Monthly Return for Equity Issuer with Hong Kong Exchanges and Clearing on 4 August 2026, covering the period ended 31 July 2026. Key disclosures are as follows:

• Share capital unchanged: Authorised/registered share capital remained at RMB 202.45 million, equivalent to 202.45 million ordinary H-shares with a par value of RMB 1 each. No increase or decrease occurred during the month.

• Issued and treasury shares stable: Issued shares (excluding treasury shares) stood at 198.91 million, while treasury shares were unchanged at 3.54 million, keeping total issued shares at 202.45 million.

• No corporate actions: The company reported no movements in share options, warrants, convertible instruments, other share-issuance agreements, or additional treasury-share transactions during July.

• Public float met: Luzhu Biotech confirmed adherence to the Main Board’s minimum public-float requirement of 25% of issued H-shares, based on publicly available information.

• Governance affirmation: The filing includes confirmations that all regulatory, listing-rule and corporate-governance obligations related to securities issuance and treasury-share management have been fulfilled.

The return underscores a period of capital stability for Luzhu Biotech with no dilution events and continued compliance with Hong Kong listing requirements.